GFHT proposals on the practical use of argatroban — With specifics regarding vaccine-induced immune thrombotic thrombocytopaenia (VITT)

Autor: Yannick Béjot, Anne Godier, B. Tardy, Isabelle Gouin-Thibault, Vincent Mémier, Guillaume Mourey, Virginie Siguret, Corinne Frere, Christine Mouton, Marie Toussaint-Hacquard, Philippe Nguyen, Bouhadjar Dahmani, Yves Gruel, Charlène Kuadjovi, Peggy Reiner, Céline Desconclois, Anne Bauters, Elodie Boissier, Alexandre Godon, Emmanuel de Maistre, Nadine Ajzenberg, Thomas Lecompte, Isabelle Crassard, Nathalie Hézard, Dominique Lasne, Georges Jourdi, Mathieu Laurichesse, Chloé James, Claire Flaujac

Publikováno v: Anaesthesia Critical Care & Pain Medicine
Anaesthesia Critical Care & Pain Medicine, Elsevier Masson, 2021, 40 (6), pp.100963. ⟨10.1016/j.accpm.2021.100963⟩
Anaesthesia Critical Care & Pain Medicine, 2021, 40 (6), pp.100963. ⟨10.1016/j.accpm.2021.100963⟩

International audience; Argatroban is a direct anti-IIa (thrombin) anticoagulant, administered as a continuous intravenous infusion; it has been approved in many countries for the anticoagulant management of heparin-induced thrombocytopaenia (HIT). A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::117089ffbef353ae160bef4a67ec0513
https://doi.org/10.1016/j.accpm.2021.100963